A new phase 1 clinical trial will investigate KMV002, an experimental therapeutic cancer vaccine for patients with metastatic prostate cancer that has become resistant to androgen-targeting treatments (mAPMR, previously mCRPC). Patients will receive either five or six doses of KMV002, a combination of SN3001C and an immune-stimulating substance known as a CpG ODN adjuvant. KMV002, […]
A new study published in Nature has identified a single transfer RNA, tRNA1Arg(UCU) as an important regulator of prostate cancer behaviour and resistance to hormone therapy. The researchers found that this tRNA is relatively abundant in androgen receptor-driven prostate cancer, but falls as tumours become more aggressive, more plastic and more neuroendocrine-like. In samples from […]
We updated you about the positive results of carotuximab (ENV-105) in this previous post. Now phase 2 data suggest that ENV-105 combined with apalutamide may substantially delay progression in metastatic castration-resistant prostate cancer (mCRPC) compared with apalutamide alone. In the randomised study, median progression-free survival reached 17.7 months with ENV-105 plus apalutamide, compared with just […]
Metastasis requires more than the ability to grow. Tumor cells that enter the bloodstream must also survive powerful mechanical forces that can physically damage or destroy them. A new preclinical study suggests that prostate cancer cells can adapt to this stress, and identifies CALB2 as a possible weak point in that adaptation. Researchers repeatedly exposed […]
AlphaFold transformed biology by predicting the three-dimensional structures of proteins. A new system called AlphaProtein Novo takes a very different step: instead of predicting proteins that already exist, it attempts to design entirely new enzymes with functions requested by researchers. The system uses machine learning to build both protein structure and amino-acid sequence around a […]
A new preclinical study has identified the NF-κB/KLF7/L1CAM axis as a potential driver of prostate cancer progression and shown that gallic acid can interfere with this pathway. KLF7 was found to promote proliferation, migration and invasion by activating L1CAM, a protein associated with aggressive and metastatic behaviour. Upstream, phosphorylation of the NF-κB p65 subunit appeared […]
A new phase 3 trial is testing 177Lu-ludotadipep (177Lu-FC705 or, simply, FC705), an experimental PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). Unlike 177Lu-PSMA-617 (Pluvicto), ludotadipep includes an albumin-binding component designed to keep the radioligand in circulation longer and increase radiation delivery to PSMA-positive tumours. Earlier studies suggest that this strategy may allow substantial […]
A newly registered randomised phase 2/3trial will test an unusual strategy in metastatic androgen pathway modulation-resistant prostate cancer (mAPMR; formerly mCRPC or castration-resistant prostate cancer): deliberately exposing resistant cancer cells to very high testosterone levels before attacking the androgen receptor again with darolutamide. The study plans to enrol 432 patients with mCRPC who have already […]
A new phase 1/2 trial will test REGN21353, a STEAP1×CD3 bispecific antibody, alone and in combination with nezastomig (REGN5678), a PSMA×CD28 costimulatory bispecific, in previously treated metastatic castration-resistant prostate cancer mCRPC (metastatic androgen pathway modulation-resistant prostate cancer mAPMR). The approach combines two different prostate cancer antigens and two complementary immune signals: CD3-mediated T-cell activation through […]
A new analysis from the randomised phase 3 NRG/RTOG 0815 trial suggests that the Decipher genomic classifier may do more than estimate prognosis: it may help predict which men with intermediate-risk prostate cancer actually benefit from adding short-term androgen deprivation therapy to dose-escalated radiotherapy. Researchers analysed tumour samples from 395 men, with a median follow-up […]